SCHEMBL6422849

SCHEMBL6422849

c1ccc(CN2CCC3(CC2)CNc2ccccc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 10/20 0.57
CYP3A4 P08684 3/20 0.57
TSHR P16473 3/20 0.57
CYP2C19 P33261 3/20 0.57
TP53 P04637 2/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2D6 P10635 2/20 0.57
ALDH1A1 P00352 2/20 0.57
CYP2C9 P11712 2/20 0.57
DRD2 P14416 1/20 0.55
NFKB1 P19838 1/20 0.55
HTR2A P28223 1/20 0.55
HTR2C P28335 1/20 0.55
MAPK1 P28482 1/20 0.55
HTR2B P41595 1/20 0.55
MTOR P42345 1/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713270 0.87 SIGMAR1 (0.59) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL29386351 0.87 SIGMAR1 (0.59) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL2109397 0.82 TNKS (0.44) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL12715975 0.82 TNKS (0.44) SIGMAR1PRNPOPRL1
SCHEMBL12716046 0.82 TNKS (0.44) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL18209383 0.81 SIGMAR1 (0.55) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL6472763 0.81 SIGMAR1 (0.52) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL3668098 0.81 POLB (0.46) SIGMAR1CYP3A4TSHRCYP2C19TP53
SCHEMBL12715818 0.80 EGLN1 (0.47) PRNP
SCHEMBL12716107 0.79 CCR5 (0.46) SIGMAR1CYP3A4DRD2NFKB1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431590-B2 Spiroindolines as modulators of chemokine receptors GLAXO GROUP LIMITED (GB) 2013-04-30 US disclosed
EP-1896466-B1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL MYERS SQUIBB CO (US) 2011-04-13 EP disclosed
US-20110034499-A1 SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS GLAXO GROUP LIMITED (GB) 2011-02-10 US disclosed
US-20110034499-A1 SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS GLAXO GROUP LIMITED (GB) 2011-02-10 US disclosed
EP-1735313-B1 SUBSTITUTED DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-06-23 EP disclosed
US-7723350-B2 Spiroindolines as modulators of chemokine receptors GLAXO GROUP LIMITED (GB) 2010-05-25 US disclosed
US-7612056-B2 schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and urinary incontinence JENSSEN PHARMACEUTICA N.V. (BE) 2009-11-03 US disclosed
US-7612056-B2 schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and urinary incontinence JENSSEN PHARMACEUTICA N.V. (BE) 2009-11-03 US disclosed
EP-1750704-B1 UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL MYERS SQUIBB CO (US) 2009-07-22 EP disclosed
US-20080318990-A1 SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS GLAXO GROUP LIMITED (GB) 2008-12-25 US disclosed
US-20070254904-A1 Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 US disclosed
US-20070254904-A1 Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 US disclosed
WO-2007002637-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed
US-6930104-B2 Heterocyclic derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040157850-A1 Novel heterocyclic derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
EP-1382598-A1 NOVEL HETEROCYCLIC DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318990-A1 SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CCR10, CXCR2 SIGMAR1 315/4885CYP3A4 2351/4885TSHR 599/4885
US-20040157850-A1 Novel heterocyclic derivatives APP, BACE1, PSEN1 SIGMAR1 1186/4885CYP3A4 3389/4885TSHR 1945/4885
US-20110034499-A1 SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CCR10, CXCR2 SIGMAR1 315/4885CYP3A4 2351/4885TSHR 599/4885
US-20070254904-A1 Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists NPSR1, PROKR2, PROKR1 SIGMAR1 588/4885CYP3A4 1557/4885TSHR 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.